Eli Lilly Spends Billions on Acquisitions to Build Non-Opioid Pain Relief Portfolio, Directly Challenging Vertex's First-Mover Advantage
Alina Collins
Eli Lilly has acquired SiteOne and 4E Therapeutics in quick succession, spending billions to enter the non-opioid pain market and take on Vertex, which already has an approved product on the market — turning a one-player race into a head-to-head contest between two pharma giants.
Why did Lilly buy two companies back-to-back?
Last year Lilly acquired SiteOne Therapeutics for up to $1 billion (including milestones), gaining chronic-pain candidate STC-004.
It then acquired 4E Therapeutics at an undisclosed price; core asset 4ET1103 showed a clean safety profile in Phase 1.
This means → Lilly wants a third growth pillar beyond weight-loss and diabetes — non-opioid pain. Both deals point to the same strategic intent.
What gives Vertex the lead?
Vertex's painkiller Journavx won FDA approval last year — the first oral non-opioid pain-signal inhibitor cleared for moderate-to-severe acute pain.
In plain terms = the drug's core selling point is "pain relief without addiction risk," and Journavx is the first to clear the regulatory bar.
Vertex is also expanding Journavx's label into diabetic peripheral neuropathy (DPN) and has a second candidate, VX-993, in Phase 2 for DPN.
Can Lilly catch up?
Lilly's pipeline is still at an early stage — years away from a marketed product.
But Lilly has staged a similar comeback before: Zepbound was approved more than two years after rival Wegovy, yet eventually overtook it in market share.
This means → first-mover advantage is not decisive. The key variable is whether later clinical data prove superior — and that readout is still years away.
Is this market big enough for two winners?
Vertex estimates roughly 80 million acute-pain patients across North America and Europe, with millions more in segments like DPN.
In plain terms = the market is large enough to support more than one winner.
Whether Lilly can replicate its weight-loss reversal depends on its pipeline outperforming Vertex's already-approved product on efficacy — an assumption that remains unproven.
Content is for reference only, not financial advice.